Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant IP Cisplatin and Chemotherapy in Gastric Cancer
NCT00296322Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2001
- Primary completion
- Dec 2007
- Countries
- 1
- Sponsor
- Asan Medical Center
- Modality
- Nanoparticles, Small Molecules
- Conditions
- gastric adenocarcinoma
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) in gastric adenocarcinoma (2 arms), sponsored by Asan Medical Center. Primary endpoint: Relapse-free Survival at 3 years. Started Oct 2001; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Mitomycin-C, Doxifluridine
Standard adjuvant chemotherapy
Mitomycin-C, Doxifluridine, Cisplatin
Intensified adjuvant chemotherapy with IP Cisplatin
03
Who it enrols
Patients with pathologically proven gastric adenocarcinoma, stage II-IV (excluding M1), aged 18-69, with adequate organ function and no prior chemo/radiotherapy.
04
Endpoints
Primary
Relapse-free Survival
Secondary
Toxicity Profile
Overall Survival
Beyond the preview
Go deeper on NCT00296322.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296322.